Diabetes
Refine Search
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Pharmaceutical
Danish diabetes care giant Novo Nordisk this morning released financials, showing that sales for the first nine months of 2018 had decreased by 2% in Danish kroner and increased 4% in local currencies to 82.1 billion Danish kroner ($12.52 billion). 1 November 2018
Pharmaceutical
There were plenty of reasons to be cheerful at Sanofi on Wednesday as the company presented its third-quarter results. 31 October 2018
Pharmaceutical
Denmark’s Novo Nordisk and French pharma major Sanofi lead the pack when it comes to delivering a standout online experience to US patients in the crowded marketplace for type 2 diabetes treatments, a study from DRG Digital Manhattan Research reveals. 23 October 2018
Biotechnology
New Jersey’s Merck & Co has reportedly backed away from taking a biosimilar follow-on product to market in the USA, despite already having tentative approval to do so from the US Food and Drug Administration. 15 October 2018
Pharmaceutical
For children and adolescents (1 to 12 October 2018
Pharmaceutical
Eisai has presented data showing the potential of its anti-obesity drug Belviq (lorcaserin hydrochloride) to prevent and cause remission of type 2 diabetes. 5 October 2018
Pharmaceutical
Germany’s Boehringer Ingelheim and the USA’s Eli Lilly have presented positive long-term results from the CARMELINA trial of Tradjenta (linagliptin) at the annual meeting of the European Association for the Study of Diabetes, in Berlin. 5 October 2018
Pharmaceutical
Boehringer Ingelheim and Eli Lilly announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in A1C versus placebo after 26 weeks of treatment, for all doses investigated (2.5, 10 and 25 mg) in the Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III program in adults with type 1 diabetes. 4 October 2018
Biotechnology
OxStem, an Oxford University spin-out developing regenerative medicine-based therapies, is launching two subsidiary companies to develop regenerative treatments for diabetes and chronic inflammation and wound healing. 4 October 2018
Pharmaceutical
Six month Phase II data on Eli Lilly’s dual GIP and GLP-1 receptor agonist, LY3298176, show “clinically meaningful blood sugar reduction and weight loss” in people with type 2 diabetes, the firm says. 4 October 2018
Biotechnology
At EASD 2018, The Pharma Letter spoke with Novo Nordisk’s chief medical officer Stephen Gough Mads Krogsgaard Thomsen about recent job losses at the company, and the seismic potential of oral semaglutide. 2 October 2018
Biotechnology
London-listed GlaxoSmithKline has presented positive data from the Harmony Outcomes study at the European Association for the Study of Diabetes. 2 October 2018
Pharmaceutical
The 54th annual meeting of the European Association for the Study of Diabetes kicks off in Berlin today, offering a week of data presentations from leading drugmakers in the diabetes space. 2 October 2018
Pharmaceutical
At its annual meeting in Berlin, the European Association for the Study of Diabetes (EASD) has launched a new initiative, aimed at enabling “the sustainability of European healthcare systems to cope with the diabetes pandemic.” 2 October 2018
Biotechnology
Copenhagen-based diabetes giant Novo Nordisk has announced that it will reduce its US workforce by around 250, just two weeks after revealing an R&D overhaul that will see around 400 jobs lost in Denmark and China. 1 October 2018
Pharmaceutical
US pharma major Eli Lill has entered into a license agreement for OWL833, an oral non-peptidic GLP-1 receptor agonist. 27 September 2018
Biotechnology
Texan drugmaker Lexicon Pharmaceuticals has announced details of clinical data for oral diabetes therapy sotagliflozin, to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD). 27 September 2018
Biotechnology
Adocia has announced details of five abstracts to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD). 27 September 2018
Pharmaceutical
Positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT2 inhibitor CVOT conducted to date have been released today. 24 September 2018
Pharmaceutical
Headline results from PIONEER 10, a Phase IIIa trial with oral semaglutide versus once-weekly subcutaneous dulaglutide, both in combination with one oral antidiabetic drug in Japanese adults with type 2 diabetes. 20 September 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze